1. Home
  2. Analysis
  3. Zejula
  4. Centrum-silver

Zejula and Centrum silver drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zejula (niraparib tosylate) and Centrum silver (ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e). Common drug interactions include dyspnoea among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Zejula and Centrum silver. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Zejula?

Zejula has active ingredients of niraparib tosylate. eHealthMe is studying from 22,014 Zejula users. Check the latest studies of Zejula.

What is Centrum silver?

Centrum silver has active ingredients of ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e. It is often used in vitamin supplementation. eHealthMe is studying from 19,997 Centrum silver users. Check the latest studies of Centrum silver.

On Jul, 08, 2026

26 people who take Zejula and Centrum silver together, and have interactions are studied.

Zejula and Centrum silver drug interactions.

What are the common drug interactions of Zejula and Centrum Silver, by gender? *:

female:

  1. Dyspnoea (difficult or laboured respiration)
  2. Hypertension (high blood pressure)
  3. Vomiting
  4. Carbohydrate antigen 125 increased
  5. Diarrhoea
  6. Anaemia (lack of blood)
  7. Asthenia (weakness)
  8. Disease progression
  9. Pruritus (severe itching of the skin)
  10. Urinary tract infection

male:

  1. Death
  2. Nausea (feeling of having an urge to vomit)

What are the common drug interactions of Zejula and Centrum Silver, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Constipation
  2. Headache (pain in head)
  3. Drug ineffective
  4. Pruritus (severe itching of the skin)
  5. Anxiety
  6. Asthenia (weakness)
  7. Back pain
  8. Blood chloride decreased
  9. Blood sodium decreased
  10. Contusion (a type of hematoma of tissue in which capillaries)

What are the existing conditions these people have? *

  1. Ovarian Cancer (cancer of ovary): 19 people, 73.08%
  2. Ovarian Cancer Metastatic (cancer of ovary spreads to other organ or parts): 2 people, 7.69%
  3. Genital Neoplasm Malignant Female (female genital tract cancer): 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Zejula and Centrum silver?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Zejula and Centrum silver:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zejula:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Centrum silver:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zejula and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Centrum silver and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on niraparib tosylate and ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e (the active ingredients of Zejula and Centrum silver, respectively), and Zejula and Centrum silver (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.